Weekly Digest – June 2025 Weekly Digest – June 2025 09 June 2025: DESTINY-Endometrial01 phase 3 Trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary advanced or recurrent endometrial cancer Daiichi Sankyo and AstraZeneca have initiated […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id